RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System

Completed · Not applicable

Conditions studied: Carcinoma, Hepatocellular, Liver Neoplasms

In brief

Hepatocellular carcinoma (HCC) is the 9th leading cause of cancer-related death in the US and one of the leading causes of death in patients with cirrhosis. Fewer than 1 in 5 high-risk patients undergo HCC screening, with lower rates in non-Caucasian and low socioeconomic status patients receiving care through safety-net health systems. Screening and follow-up failures lead to more advanced cancers, when curative therapies are not available and survival is significantly worse. Over 60% of HCC are diagnosed at advanced stages, due to poor recognition of high-risk patients, underuse of screening among these patients, and poor follow-up of abnormal screening tests. To address these barriers, the investigators propose to conduct a comparative effectiveness research randomized controlled trial of three screening strategies among a socioeconomically disadvantaged and racially diverse cohort of cirrhotic patients at high risk for developing HCC. Overall, 1800 patients attending Parkland, the Dallas safety-net health system, will be randomized to: * Group 1: Usual care, with visit-based HCC screening per discretion of individual providers * Group 2: Mailed HCC screening invitation outreach to eligible patients (low resource intensity) * Group 3: Mailed HCC screening invitation outreach to eligible patients combined with centralized patient navigation to promote screening completion and follow-up (high resource intensity) Through three specific aims, this effectiveness research randomized controlled trial will: * Aim 1: Engage stakeholders in design and implementation of HCC screening outreach interventions. * Aim 2: Compare the clinical effectiveness and patient acceptability of the intervention strategies to increase completion of one-time and repeat HCC screening. * Aim 3: Evaluate whether intervention effects are moderated by patient sex, race, ethnicity, English proficiency, and connectedness to primary care. The screening intervention strategies combine EMR-enabled case identification, system-level screening outreach, and patient navigation to improve identification of previously unrecognized cirrhotic patients, promote HCC screening completion, and facilitate follow-up of abnormal screening tests. This study will engage stakeholders throughout the research process, evaluate the effectiveness and acceptability of HCC screening strategies, and determine which patient subgroups benefit the most.

Key facts

Study ID

NCT02312817

Run by

University of Texas Southwestern Medical Center

People needed

1800

Starts

2014-12-01

Expected to finish

2017-08-01

Last updated by the study team

2025-07-15

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Parkland patients ≥ 21 years of age
• Diagnosis of cirrhosis or meets criteria for suspected cirrhosis
• ≥ 1 outpatient visit during 12 months prior to randomization
• Contact information on file
• English or Spanish speaking

You may not qualify if…

• HCC or suspicious mass on imaging
• Any malignancy except malignant neoplasm of skin
• Metastatic solid tumor
• Palliative care referral
• Liver transplant
• Child Pugh C

Where it is running

• Parkland Health & Hospital System — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.